LeadStory

CNBC

Pfizer and Novo Nordisk both raise bids for Metsera

CNBC · Just In
CNBC
CNBC
Just In

CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.

Breakdown
  • A bidding war has emerged between Pfizer and Novo Nordisk for control of Metsera.
  • Novo Nordisk countered Pfizer's initial offer with a structure providing immediate payment to Metsera shareholders, leading Pfizer to file a lawsuit and raise its own bid. 15s
  • Novo Nordisk's latest offer totals $86.20 per share, including a $24 contingent value right, and has been deemed superior to Pfizer's bid. 1m 2s
  • Pfizer has four days to respond to Novo's superior bid, while a court considers Pfizer's request for a temporary restraining order against Novo's offer structure. 1m 25s
  • Pfizer CEO Albert Bourla argued that Novo Nordisk's offer faces significant antitrust risks and may not be completed. 2m 7s
HealthBusiness